Clinical Trial Update: Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating epirubicin and paclitaxel, with or without capecitabine, as first-line therapy for metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ELLENCE (Epirubicin hydrochloride)
• PACLITAXEL (PACLITAXEL)
• Xeloda (capecitabine)

Snippet

Sponsor: Thomas Hatschek | Conditions: Metastatic Breast Cancer | Phase 3 | Status: COMPLETED